Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Two Cycles Versus Four Cycles of Capecitabine Combined Oxaliplatin Concurrent Radiotherapy as First-line Therapy for Chinese Locally Advanced Esophageal Squamous Cell Carcinomas, an Open Randomised Phase III Cilinical Trial

NCT02604615 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Henan University of Science and Technology as lead sponsor.

NCT NCT02604615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02604615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Two Cycles Versus Four Cycles of Capecitabine Combined Oxaliplatin Concurrent Radiotherapy as First-line Therapy for Chinese Locally Advanced Esophageal Squamous Cell Carcinomas, an Open Randomised Phase III Cilinical Trial
Lead sponsor
The First Affiliated Hospital of Henan University of Science and Technology
Phase
Phase 3
Overall status
Unknown status
Start date
October 31, 2014
Completion date
December 31, 2020
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal neoplasms, stage iii esophageal squamous cell carcinoma